Search Results - "Pecuchet, N"

Joined analysis of sarcomatoid carcinoma (SC) mutational profiles: Comparison of lung versus head and neck cancer by Pecuchet, N., Touachi, R., Ben Lakhdar, A., Fallet, V., Rabbe, N., Blons, H., Lemoine, A., Antoine, M., Tenam, S., Laurent-Puig, P., Wislez, M.

Get full text

468 Validity of next generation sequencing in routine care for non-small cell lung cancer diagnosis by Legras, A, Pecuchet, N, Tallet, A, Guyard, A, Mansuet-Lupo, A, Prieur, E. Giroux-Le, Giraudet, V, Gibault, L, Damotte, D, Julie, C, Alifano, M, Pimpec-Barthes, F. Le, Laurent-Puig, P, Fabre, E, Blons, H

Get full text

208 Different prognostic impact of STK11 mutations in Non-Small-Cell Lung Cancer (NSCLC) illustrates the switch from a tumor suppressor to an oncogene by Pecuchet, N, Laurent-Puig, P, Mansuet-Luppo, A, Legras, A, Alifano, M, Pallier, K, Didelot, A, Gibault, L, Danel, C, Just, P.A, Le Pimpec-Barthes, F, Damotte, D, Fabre, E, Blons, H

Get full text

Molecular classification of pulmonary sarcomatoid carcinomas suggests new therapeutic opportunities by Pécuchet, N., Vieira, T., Rabbe, N., Antoine, M., Blons, H., Cadranel, J., Laurent-Puig, P., Wislez, M.

“…Pulmonary sarcomatoid carcinoma (SC) is a rare disease with poor prognosis and with strong inter- and intratumor heterogeneity. However, molecular…”
Get full text

Triple combination of bevacizumab, gemcitabine and platinum salt in metastatic collecting duct carcinoma by Pécuchet, N., Bigot, F., Gachet, J., Massard, C., Albiges, L., Teghom, C., Allory, Y., Méjean, A., Escudier, B., Oudard, S.

“…Collecting duct carcinoma (CDC) is a rare and aggressive subtype of kidney cancer that responds to platinum-based chemotherapy. Recent phase II trials have…”
Get full text

Histone deacetylase inhibitors: highlight on epigenetic regulation by Pécuchet, N, Cluzeau, T, Thibault, C, Mounier, N, Vignot, S

“…HDAC, by modifiing relations between DNA and histones, are major proteins of the epigenetic regulation. They play part in the signal transduction and in many…”
Get more information

Implications of ALK (anaplastic lymphoma kinase) in oncohematology by Cluzeau, T, Pécuchet, N, Mounier, N, Vignot, S

“…The anaplastic lymphoma kinase gene (ALK) code for a receptor tyrosine-kinase. The fusion proteins from the ALK gene have been identified in oncohaematology…”
Get more information

Sorafenib in advanced melanoma: a critical role for pharmacokinetics? by Pécuchet, N, Lebbe, C, Mir, O, Billemont, B, Blanchet, B, Franck, N, Viguier, M, Coriat, R, Tod, M, Avril, M-F, Goldwasser, F

“…Background: Inter-patient pharmacokinetic variability can lead to suboptimal drug exposure, and therefore might impact the efficacy of sorafenib. This study…”
Get full text

IHC, FISH, CISH, NGS in non-small cell lung cancer: What changes in the biomarker era? by Hamard, C, Mignard, X, Pecuchet, N, Mathiot, N, Blons, H, Laurent-Puig, P, Leroy, K, Lupo, A, Chapron, J, Giraud, F, Arrondeau, J, Goldwasser, F, Alifano, M, Damotte, D, Wislez, M

“…Lung cancer is the leading cause of cancer deaths in France, with about 30,000 deaths per year. The overwhelming majority (90 %) are tobacco-related. The…”
Get full text

724P A prospective phase II study of gemcitabine plus platinum in combination with bevacizumab for metastatic renal medullary and collecting duct carcinoma (GETUG-AFU 24, BEVABEL trial) by Thibault, C., Elaidi, R.T., Fléchon, A., Albiges, L., Joly, C., Barthélémy, P., Gross Goupil, M., Chevreau, C.M., Joly, F., Rolland, F., Laguerre, B., Gravis, G., Brihoum, M., Timsit, M-O., Pecuchet, N., Allory, Y., Oudard, S.

Get full text

Therapeutic impact of molecular diagnosis in metastatic non-small cell lung cancer: targeted therapies in 2013 by Pecuchet, N, Bigot, F, Henni, M, Fabre, E

“…Recent advances in the molecular characterization of metastatic unresectable lung cancers have markedly improved the management of patients. Today, molecular…”
Get full text

1896PDJoined analysis of sarcomatoid carcinoma (SC) mutational profiles: Comparison of lung versus head and neck cancer by Pecuchet, N, Touachi, R, Ben Lakhdar, A, Fallet, V, Rabbe, N, Blons, H, Lemoine, A, Antoine, M, Tenam, S, Laurent-Puig, P, Wislez, M

Get full text

Obesity and lung cancer: incidence and repercussions on epidemiology, pathology and treatments by Rivera, C, Pecuchet, N, Wermert, D, Pricopi, C, Le Pimpec-Barthes, F, Riquet, M, Fabre, E

“…Obesity and lung cancer are major public health problems. The purpose of this work is to review the data concerning this association. We report clinical and…”
Get full text

Whole exome sequencing (WES) and RNA sequencing (RNA-seq) in routine clinical practice for colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) patients (pts) by Perkins, G., Fabre, E., Fallet, V., Blons, H., Pecuchet, N., Gounant, V., Gibault, L., Michel-Jeljeli, E., Antoine, M., Roux, E., Wislez, M., Le Corre, D., Leroy, K., Lacave, R., Taieb, J., Cadranel, J., Laurent-Puig, P.

Get full text

Radiological-Histological Size Correlation in Triple-Negative Breast Cancer (Tnbc) by Thibault, C., Gosset, M., Chamming'S, F., Lefrere-Belda, M., Pecuchet, N., Fournier, L., Roussel, H., Oudard, S., Lécuru, F., Medioni, J.

Get full text

292PRADIOLOGICAL-HISTOLOGICAL SIZE CORRELATION IN TRIPLE-NEGATIVE BREAST CANCER (TNBC) by Thibault, C., Gosset, M., Chamming'S, F., Lefrere-Belda, M., Pecuchet, N., Fournier, L., Roussel, H., Oudard, S., Lécuru, F., Medioni, J.

“…Abstract Aim: Preoperative size of breast tumors is a crucial parameter for guiding modality of surgery and neoadjuvant chemotherapy (NAC). Mammography (MG)…”
Get full text

Plasmatic Tumor Dna Assessments Predict Clinical Outcome in Egfr-Mutated Non-Small Cell Lung Cancer Patients Treated By Egfr Inhibitors by Pecuchet, N., Didelot, A., Zonta, E., Lours, C., Gibault, L., Rice, N., Laurent-Puig, P., Fabre, E., Taly, V., Blons, H.

Get full text

1280PPLASMATIC TUMOR DNA ASSESSMENTS PREDICT CLINICAL OUTCOME IN EGFR-MUTATED NON-SMALL CELL LUNG CANCER PATIENTS TREATED BY EGFR INHIBITORS by Pecuchet, N., Didelot, A., Zonta, E., Lours, C., Gibault, L., Rice, N., Laurent-Puig, P., Fabre, E., Taly, V., Blons, H.

“…Abstract Aim: We aimed to study the dynamics of plasmatic EGFR mutations by qualitative (Q-PCR) and quantitative (droplet PCR) methods in EGFR-mutated lung…”
Get full text

Crizotinib in Patients with Lung Cancer and Ros1 Fusion: Results from the European Cohort Euros1 by Mazières, J., Zalcman, G., Crinò, L., Biondani, P., Filleron, T., Dingemans, A.C., Lena, H., Monnet, I., Rothschild, S.I., Cappuzzo, F., Thiberville, L., Barlesi, F., Dziadziuszko, R., Smit, E.F., Wolf, J., Spirig, C., Pecuchet, N., Diebold, J., Milia, J., Gautschi, O.

Get full text

939TiPRANDOMIZED DOUBLE BLIND PLACEBO-CONTROLLED PHASE II TRIAL OF NINTEDANIB VERSUS PLACEBO IN ADVANCED OVARIAN CANCER (OC) PATIENTS TREATED WITH NEO-ADJUVANT CHEMOTHERAPY (NACX) AND INTERVAL DEBULKING SURGERY (IDS):THE CHIVA TRIAL FROM GINECO by Ferron, G., Lesoin, A., Ray-Coquard, I.L., Joly Lobbedez, F., De Rauglaudre, G., Meunier, J., Pecuchet, N., Lortholary, A., Kaminsky-Forrett, M., Malaurie, E., Hamizi, S., Berton-Rigaud, D., Louvet, C., Alexandre, J., Pujade-Lauraine, E.

“…Abstract Background: Initial cytoreductive surgery followed by 6 cycles of platinum-taxane based chemotherapy (Cx) remains the standard of care for advanced…”
Get full text